Search results for "Urea"
showing 10 items of 888 documents
Multimodal approaches to the treatment of hepatocellular carcinoma.
2008
The prevalence of hepatocellular carcinoma in Europe and the US is increasing and is currently the leading cause of death in patients with cirrhosis. Surveillance programs for patients with cirrhosis aim to detect tumors at an early stage, when the greatest therapeutic benefits can be achieved. Curative treatments for early-stage tumors include liver transplantation, resection and percutaneous ablation. Transarterial chemoembolization (TACE) and sorafenib can improve survival for patients with intermediate and advanced tumors, respectively. In clinical practice, combination therapies are often used, despite limited evidence to support this approach from randomized controlled trials. Combina…
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
2015
According to the guidelines of the European Association for the Study of the Liver (EASL), patients affected from hepatocellular carcinoma (HCC) can be classified according to the Barcelona Clinic Liver Cancer (BCLC) staging system. This classification system divides HCC patients in five stages (0, A, B, C and D) on the basis of a number of prognostic and treatment- related variables such as tumor status and liver function. A specific treat ment approach is then proposed for each of the above-mentioned stages. Transarterial chemoembolization (TACE) is recommended as first-line therapy in the treatment of patients with intermediate-stage (BCLC-B class) HCC [1]. The efficacy of this procedure…
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
2018
The hepatocellular carcinoma (HCC) treatment landscape changed a decade ago, with sorafenib demonstrating survival benefit in the first-line setting and becoming the first systemic therapy to be approved for HCC. More recently, regorafenib and nivolumab have received approval in the second-line setting after sorafenib, with further positive phase 3 studies emerging in the first line (lenvatinib non-inferior to sorafenib) and second line versus placebo (cabozantinib and ramucirumab). A key recommendation in the management of patients receiving sorafenib is to promote close communication between the patient and the physician so that adverse events (AEs) are detected early and severe AEs can b…
Immune oncology in hepatocellular carcinoma-hype and hope.
2017
CCDC 1425265: Experimental Crystal Structure Determination
2016
Related Article: T. Mäkelä, K. Rissanen|2016|Dalton Trans.|45|6481|doi:10.1039/C6DT00414H
CCDC 1469018: Experimental Crystal Structure Determination
2016
Related Article: Filip Topić and Kari Rissanen|2016|J.Am.Chem.Soc.|138|6610|doi:10.1021/jacs.6b02854
CCDC 1469012: Experimental Crystal Structure Determination
2016
Related Article: Filip Topić and Kari Rissanen|2016|J.Am.Chem.Soc.|138|6610|doi:10.1021/jacs.6b02854
CCDC 1469009: Experimental Crystal Structure Determination
2016
Related Article: Filip Topić and Kari Rissanen|2016|J.Am.Chem.Soc.|138|6610|doi:10.1021/jacs.6b02854
CCDC 1478714: Experimental Crystal Structure Determination
2016
Related Article: Toni Mäkelä, Anniina Kiesilä, Elina Kalenius and Kari Rissanen|2016|Chem.-Eur.J.|22|14264|doi:10.1002/chem.201602362
CCDC 953983: Experimental Crystal Structure Determination
2013
Related Article: Ana Gimeno, Ana B. Cuenca, Samuel Suárez-Pantiga, Carmen Ramírez de Arellano, Mercedes Medio-Simón, Gregorio Asensio|2014|Chem.-Eur.J.|20|683|doi:10.1002/chem.201304087